A phase II, multicenter, single-arm trial of eribulin as first or second line chemotherapy for HER2-negative advanced or metastatic breast cancer: Evaluation of efficacy, safety, and patient-reported outcomes.

Mitsuhiko Iwamoto,Kosei Kimura,Satoru Tanaka,Daigo Yamamoto,Katsuhide Yoshidome,Hiroyuki Ogura,Risa Terasawa,Nobuki Matsunami,Yuko Takahashi,Toshikatsu Nitta,Takashi Morimoto,Hiroya Fujioka,Kanako Kawaguchi,Kazuhisa Uchiyama

Journal of Clinical Oncology（2018）

Cited 0|Views5

No score

Abstract

e13059Background: Although eribulin is a suitable option for early-line treatment of metastatic breast cancer (MBC), data on first- or second-line use of eribulin for human epidermal growth factor ...

Translated text

Key words

metastatic breast cancer,second line chemotherapy,eribulin,breast cancer,single-arm,patient-reported

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined